January 21, 2022
1 min read
Save
CHIEF-HF
Issue: January 2022
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Canagliflozin (Invokana, Janssen) vs. placebo for symptom improvement in patients with HF.